Market Place
Sourcing Support
Praluent Injection Receives FDA Approval to Treat High Cholesterol
11 Mar 2024 //
GLOBENEWSWIRE
Regeneron`s Biologic Praluent (alirocumab) Receives Approval in the U.S.
08 Mar 2024 //
FDA
Federal judge denies Amgen`s motion to dismiss Regeneron antitrust case
22 Mar 2023 //
ENDPTS
Supreme Court calls on top government lawyer to weigh PCSK9 patent appeal
21 Apr 2022 //
ENDPTS
Innovent Biologics` cholesterol drug IBI306 meets main goal in 2 studies
18 Feb 2022 //
SEEKING ALPHA
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
15 Nov 2021 //
BIOSPACE
Esperion to cute 170 staffers as heart disease pill sputters
19 Oct 2021 //
YAHOOFINANCE
Amgen`s Repatha gains FDA nod for genetic cholesterol disorder
28 Sep 2021 //
FIERCEPHARMA
Sanofi Files Opposition to Amgen’s Petition on Praluent Patents
08 Jun 2021 //
GOODWIN
Amgen Petitions Federal Circuit to Reconsider Decision Invalidating Praluent
23 Apr 2021 //
BIGMOLECULE
FDA Okays New Indication for Alirocumab in Homozygous FH
02 Apr 2021 //
MEDSCAPE
FDA approves Regeneron drug for rare, genetic form of high cholesterol
16 Feb 2021 //
BIOPHARMADIVE
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi
11 Feb 2021 //
PRNEWSWIRE
Sanofi, Regeneron win EU patent case against Amgen over PCSK9 antibodies
30 Oct 2020 //
FIRSTWORDPHARMA
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy Featured
17 Sep 2020 //
BIOSPACE
Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
31 Aug 2020 //
FIERCE PHARMA
ESC: Amgen chases pediatric use for cholesterol-buster Repatha
29 Aug 2020 //
FIERCE PHARMA
Regeneron flashes ‘great advance` in the NEJM for that other cholesterol drug
19 Aug 2020 //
ENDPOINTSNEWS
Regeneron’s cholesterol drug evinacumab claims February FDA date
17 Aug 2020 //
PHARMAPHORUM
Amgen: Japan Supreme Court Rejects Sanofi Appeal on PCSK9 Patent
09 May 2020 //
BLOOMBERGLAW
Amgen v. Sanofi Praulent® Litigation Once Again on Appeal
15 Apr 2020 //
BIGMOLECULEWATCH
Alirocumab Substantially Reduces Cholesterol in Adult Patients with HoFH
31 Mar 2020 //
ACC
Sanofi Aventis Praluent (Alirocumab ) Receives Supplemental Approval in US
12 Mar 2020 //
FDA
Can Regeneron weather Novartis’ Beovu and new Sanofi deal?
06 Feb 2020 //
FIERCE PHARMA
Regeneron’s Yancopoulos is still bitter over Praluent sales
15 Jan 2020 //
STAT
Regeneron to lay off field staff as it rejigs Sanofi partnership
03 Jan 2020 //
FIERCE PHARMA
Amgen’s Cholesterol Drug Spat a Turning Point on Patents
30 Dec 2019 //
BLOOMBERG
Can Dupixent steal half of a $21B eczema market? Not so fast
12 Dec 2019 //
FIERCE PHARMA
Sanofi and Regeneron to simplify antibody partnership
12 Dec 2019 //
PHARMACEUTICAL-TECHNOLOGY
MedCo builds its case for star cholesterol RNAi therapy
25 Sep 2019 //
ENDPTS
Clean data tee Medicines Company up for PCSK9 scrap
03 Sep 2019 //
FIERCE BIOTECH
U.S. District Court Invalidates Amgen Patents Over Cholesterol Med
30 Aug 2019 //
BIOSPACE
Sanofi receive favourable US court ruling in Praluent patent litigation
30 Aug 2019 //
PHARMABIZ
Praluent, Repatha face major new PCSK9 threat
27 Aug 2019 //
FIERCE PHARMA
Medicines Co.`s PCSK9 drug succeeds in first Phase 3 test
27 Aug 2019 //
BIOPHARMADIVE
Can Lilly JAK Olumiant really challenge Dupixent in dermatitis?
26 Aug 2019 //
FIERCE PHARMA
Regeneron preps for 2020 filing for new cholesterol drug after trial success
18 Aug 2019 //
PHARMAPHORUM
Novartis fires brother scientists alleged to be involved in data manipulation
15 Aug 2019 //
CNBC
AveXis top science leaders exit amid Zolgensma debacle
14 Aug 2019 //
FIERCE PHARMA
With patent win, Amgen ready to block PCSK9 rivals in Germany
13 Jul 2019 //
FIERCE PHARMA
Pharma takes Wi-Fi targeting to the doctor`s office to reach waiting patients
04 Jul 2019 //
FIERCE PHARMA
Analysis shows The Medicines Company/Alnylam drug inclisiran safe
28 May 2019 //
ENDPTS
Med Co, Alnylam`s inclisiran cuts cholesterol long-term
21 May 2019 //
FIERCE BIOTECH
ICER seeks to make drug price research more accessible
21 May 2019 //
BIOPHARMADIVE
US FDA approves Sanofi`s Praluent to prevent heart attack, stroke
30 Apr 2019 //
PHARMABIZ
As Praluent Q1 sales miss Wall Street expectations, FDA expands drug’s label
30 Apr 2019 //
ENDPTS
Sanofi Aventis Praluent (Alirocumab) Receives Supplemental Approval in US
30 Apr 2019 //
FDA
Sanofi, Regeneron score a Praluent boost with new CV nod
29 Apr 2019 //
FIERCE PHARMA
Sanofi gets cardio outcomes claim for Praluent in EU
18 Mar 2019 //
PM LIVE
Praluent® approved in European Union to reduce the risk of cardiovascular events
15 Mar 2019 //
PR NEWSWIRE
ICER Publishes Final New Evidence Update for Alirocumab
18 Feb 2019 //
ICER
Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
12 Feb 2019 //
REUTERS
Sanofi, Regeneron offer Praluent® (alirocumab) at new reduced U.S. list price
11 Feb 2019 //
PR NEWSWIRE
U.S. top court rejects Amgen over cholesterol medication patent fight
07 Jan 2019 //
REUTERS
ODYSSEY OUTCOMES investigators highlight Praluent® (alirocumab) Injection
11 Nov 2018 //
PR NEWSWIRE
NEJM publishes +ve results from Praluent (alirocumab) Injection CV trial
08 Nov 2018 //
PRESS RELEASE
Regeneron continues New York expansion with $800M project, 1,500 jobs
13 Sep 2018 //
FIERCE PHARMA
Sanofi and Regeneron`s Praluent closes in on sales-boosting CV nod
12 Sep 2018 //
FIERCE PHARMA
